Patents by Inventor Simone Schmitt
Simone Schmitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132575Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.Type: ApplicationFiled: October 29, 2023Publication date: April 25, 2024Inventors: Marcel WEBER, Simone SCHMITT, Christoph ESSLINGER, Thomas SCHACHTNER, Uyen HUYNH-DO, Maurizio PROVENZANO
-
Patent number: 11919943Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.Type: GrantFiled: October 25, 2022Date of Patent: March 5, 2024Assignees: MEMO THERAPEUTICS AG, UNIVERSITÄT BERN, UNIVERSITÄT ZÜRICHInventors: Marcel Weber, Simone Schmitt, Christoph Esslinger, Thomas Schachtner, Uyen Huynh-Do, Maurizio Provenzano
-
Publication number: 20230203151Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: August 5, 2022Publication date: June 29, 2023Applicant: Cell Medica, Inc.Inventors: Annemarie HONEGGER, Titus KRETZSCHMAR, Simone SCHMITT, Abdijapar SHAMSHIEV, Stefanie GRABULOVSKI
-
Publication number: 20230192816Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.Type: ApplicationFiled: October 25, 2022Publication date: June 22, 2023Inventors: Marcel WEBER, Simone SCHMITT, Christoph ESSLINGER, Thomas SCHACHTNER, Uyen HUYNH-DO, Maurizio PROVENZANO
-
Publication number: 20230009582Abstract: Anti-Siglec-9 antibody molecules or binding fragments thereof are disclosed. These Anti-Siglec-9 antibody molecules or binding fragments can be used to treat cancer, acute or chronic hepatitis B.Type: ApplicationFiled: November 13, 2020Publication date: January 12, 2023Inventors: Heinz LÄUBLI, Simone SCHMITT, Christoph ESSLINGER
-
Patent number: 11407824Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: GrantFiled: February 6, 2020Date of Patent: August 9, 2022Assignee: Cell Medica, Inc.Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
-
Publication number: 20220220195Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: January 28, 2022Publication date: July 14, 2022Inventors: Stefanie Grabulovski, Titus KRETZSCHMAR, Simone SCHMITT, Abdijapar SHAMSHIEV, Thorsten Alexander SCHAFER
-
Patent number: 11267884Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: GrantFiled: March 18, 2020Date of Patent: March 8, 2022Assignee: Cell Medica Inc.Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
-
Publication number: 20200362028Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: February 6, 2020Publication date: November 19, 2020Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
-
Publication number: 20200239565Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: March 18, 2020Publication date: July 30, 2020Inventors: Stefanie GRABULOVSKI, Titus KRETZSCHMAR, Simone SCHMITT, Abdijapar SHAMSHIEV, Thorsten Alexander SCHAFER
-
Patent number: 10626171Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: GrantFiled: August 30, 2018Date of Patent: April 21, 2020Assignee: Cell Medica Switzerland AGInventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
-
Publication number: 20180362642Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: August 30, 2018Publication date: December 20, 2018Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
-
Patent number: 10077302Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: GrantFiled: July 6, 2016Date of Patent: September 18, 2018Assignee: Cell Medica Switzerland AGInventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schafer
-
Publication number: 20180258165Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: February 14, 2018Publication date: September 13, 2018Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
-
Patent number: 9914772Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: GrantFiled: June 16, 2015Date of Patent: March 13, 2018Assignee: Cell Medica Switzerland AGInventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
-
Publication number: 20170051054Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: July 6, 2016Publication date: February 23, 2017Inventors: Stefanie GRABULOVSKI, Titus KRETZSCHMAR, Simone SCHMITT, Abdijapar SHAMSHIEV, Thorsten Alexander SCHAFER
-
Patent number: 9404930Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: GrantFiled: November 5, 2013Date of Patent: August 2, 2016Assignee: DELENEX THERAPEUTICS AGInventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schäfer
-
Publication number: 20160194392Abstract: The present invention relates to anti-IL-1 beta antibodies and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable. Such antibodies can be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: June 16, 2015Publication date: July 7, 2016Inventors: Annemarie Honegger, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Stefanie Grabulovski
-
Publication number: 20140134183Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.Type: ApplicationFiled: November 5, 2013Publication date: May 15, 2014Applicant: Delenex Therapeutics AGInventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev
